Efficacy and safety of denosumab and teriparatide versus oral bisphosphonates to treat postmenopausal osteoporosis: a systematic review and meta-analysis.

Front Endocrinol (Lausanne) · 2024 · PMC11402677 · PMID 39286276

Europe PMC DOI

hedged sentence

0.2300

closest p · 4.6× alpha

0.2300

boldest claim

The sentences

did not reach statistical significancep=0.23not close (p > 0.1)

However, the difference in percentage changes in femoral neck BMD between the teriparatide and oral bisphosphonates groups did not reach statistical significance [teriparatide arm: RR=0.74, 95%CI:-0.46–1.94, p=0.23].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.